Friday, September 29, 2023


Biotechnology News Magazine

TAU Systems Signs an Agreement with The University of Texas at Austin

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

TAU Systems, a producer of ultrafast, compact plasma accelerators, today announced the signing of a suite of crucial agreements with The University of Texas at Austin (UT Austin) to focus on the fundamental elements of laser-plasma interactions, advancing the science and technology of compact accelerator systems and advanced light sources, with the goal of making these tools widely available to a broad range of end-users and industry.

TAU Systems is developing the world’s first compact particle accelerators and specialized X-ray free-electron lasers that combine the capabilities of large accelerators with a small footprint to provide easy and affordable beam-time access for any company or research institute. Led by experts in laser-driven particle accelerators, TAU is democratizing accelerator access for the progress of biotechnology, nuclear and battery technology, and more.

These agreements included a Sponsored Research Agreement and a Patent License Agreement. The Sponsored Research Agreement enables TAU Systems and UT Austin personnel to work together in laboratories and collaborate on researching the fundamental elements of laser-plasma interaction. TAU will fund UT Austin laboratory staff in exchange for shared access to UT Austin laboratories, including TAU personnel working in the capacity of UT Austin research affiliates.

The Patent License Agreement establishes an exclusive license to a foundational patent on laser-plasma interaction for particle acceleration. As part of the agreement, UT Austin has been issued shares in TAU Systems.

“Thanks to our Sponsored Research Agreement, we will begin utilizing the state of the art UT Austin Tabletop Terawatt Laboratory laser, which enables our team to further explore the fundamental elements of laser-plasma interaction, a key part of our compact plasma accelerators,” said Bjorn Manuel Hegelich, TAU Systems CEO. “We have also signed a Patent License Agreement with UT Austin that grants us an exclusive license to a foundational patent on laser-plasma interaction for particle acceleration.”

Christine Dixon Thiesing, associate vice president for Discovery to Impact at UT Austin said, “This collaboration with TAU Systems highlights how the impact of academic research can be greatly amplified through startups. UT Austin is committed to supporting businesses like TAU Systems in their efforts to bring products and services to the market that change the world.”

This announcement further expands TAU Systems’ network with the world’s leading academic institutes and builds on the recently announced partnership with Lawrence Berkeley National Laboratory to demonstrate the U.S.’s first laser-driven vacuum UltraViolet free-electron laser at the BELLA Center.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine